Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Robert S. Busch's publication output changed over time?
ScholarIQpublication output · 2017–2024
Output grew0% over the shown period — from 1 works in 2017 to 1 in 2024.
1
2
4
1
1
1
201720182019202120222024
What are the most-cited papers on Robert S. Busch?
ScholarIQmost cited works
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R Tuttle, Mark Lakshmanan, Brian Rayner, Robert S. Busch, Alan G. Zimmermann, D. Bradley Woodward, Fady T. Botros
The Lancet Diabetes & Endocrinology. 2018645 Citations
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress, George L. Bakris, Ricardo Correa-Rotter, Fan Fan Hou, Dalane W. Kitzman, Donald Kohan, Hirofumi Makino, John J.V. McMurray, Joel Z. Melnick, Michael G. Miller, Pablo E. Pérgola, Vlado Perkovic, Sheldon W. Tobe, Tingting Yi, Melissa Wigderson, Dick de Zeeuw, Alicia Elbert, Augusto Vallejos, Andres Alvarisqueta, Laura Maffei, Luis I. Juncos, Javier de Arteaga, Gustavo Greloni, Eduardo Farias, A Zucchini, Daniel Vogel, Ana María Cusumano, Juan Carlos Santos, Margaret B. Fraenkel, Martin Gallagher, Timothy M. E. Davis, Shamasunder Acharya, Duncan Cooke, Michael Suranyi, Simon D. Roger, Nigel D. Toussaint, Carol A. Pollock, Doris Chan, Stephen Stranks, Richard J. MacIsaac, Zoltán Endre, Alice Schmidt, Rudolf Prager, Gert Mayer, Xavier Warling, Michel Jadoul, Jean Hougardy, Chris Vercammen, Bruno Van Vlem, Pieter Gillard, Adriana Costa e Forti, João Borges, Luis Santos Canani, Freddy G. Eliaschewitz, Silmara Leite, Fadlo Fraige Filho, Raphael Paschoalin, José A. Moura-Neto, Luciane Mônica Deboni, Irene de Lourdes Noronha, Cíntia Cercato, Carlos Alberto Prompt, Maria Teresa Zanella, Nelson Rassi, Domingos O. d’Avila, Rosângela Milagres, João Soares Felício, Roberto Pecoits‐Filho, Miguel C. Riella, João Eduardo Nunes Salles, Elizete Keitel, Sérgio Antônio Draibe, Celso Amodeo, J. T. Youmbissi, Louise Roy, Serge Cournoyer, Shivinder Jolly, Vincent Pichette, Gihad Nesrallah, Harpreet S. Bajaj, Hasnain Khandwala, Ronnie Aronson, Richard Goluch, Paul Kwong Hang Tam, Christian Rabbat, Sheldon W. Tobe, G. HOWARD BAILEY, S. P. Chow, A Castillo, Alfredo Danin Vargas, Fernando González, Rodrigo Muñoz, Vicente Gutiérrez, Gonzalo Godoy, Hongwen Zhao, Zhangsuo Liu, Ming‐Hui Zhao, Xiaohui Guo
The Lancet. 2019620 CitationsOPEN ACCESS
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard, Julio Rosenstock, Luís Henrique Santos Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Lindberg, Ildiko Lingvay, ANETTE L. SØNDERGAARD, Marianne Bach Treppendahl, Eduard Montanya, PIONEER 2 Investigators, Pablo Jordão Alcântara Cruz, Luis De Loredo, Cecilia Luquez, Maria Alejandra Moisello, Gustavo Akerman Augusto, Marise Lazaretti Castro, Luís Henrique Santos Canani, Branko Akrap, Tomislav Bulum, Dario Rahelić, Ivana Sunic-Grcic, Srecko Tusek, Iakovos Avramidis, Marian Benroubi, Triantafyllos Didangelos, Gerasimos Karousos, Emmanouil Pagkalos, Christos Sampanis, Maria Somali, Zsolt Domboróczki, Péter Faludi, Zsolt Gaál, Piroska Kis-Gombos, Győző Kocsis, Zoltán Márton, Zsolt Sudár, Silvio Buscemi, Alberto Di Carlo, Francesco Dotta, Alessandra Gambineri, Davide Lauro, Marianna Maranghi, Małgorzata Arciszewska, Janusz Gumprecht, Krystyna Matuszewska, Ewa Skokowska, Teresa Stasinska, Svetlana Feofanova, Е. О. Филиппова, G. R. Galstyan, Leylya Gaysina, М. А. Куницына, Л. А. Суплотова, Slobodan Antić, Aleksandar Djukić, Milena Mitrović, Milica Pešić, Edita Stokić, Esteban Jódar, Encarna Martínez, Pedro Mezquita Raya, Eduard Montanya, Cristobal Morales Portillo, Mercè Pérez Vera, Margarita Fernández, Patricia San José, Manel Terns Riera, Apussanee Boonyavarakul, Chaicharn Deerochanawong, Apiradee Sriwijitkamol, Dilawar Ajani, Eddie Armas, Kim Barbel-Johnson, Darlene Bartilucci, Gholamreza Bonabi, Robert S. Busch, David Butuk, Kevin D. Cannon, Craig Chase, Louis Chaykin, Vasundhara Cheekati, Thomas R. A. Davis, Belkis Delgado, Neil Farris, Mark Graves, Chi Ha, Linda Harper, Sharon J. Herring, Mitzie Hewitt, Daniel S. Hsia, Richard A. Jackson, Michael Jardula, Mark Joyce, Mario Juarez, Anoop Kapoor, Dennis G. Karounos, David Kayne, Audrey Lacour, Gilbert Ledesma
Diabetes Care. 2019455 CitationsOPEN ACCESS
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Bernard Zinman, Vaishali Bhosekar, Robert S. Busch, Ingrid Holst, Bernhard Ludvik, Desirée Thielke, James Thrasher, Vincent Woo, Athena Philis‐Tsimikas
The Lancet Diabetes & Endocrinology. 2019374 Citations
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund, Jan W. Eriksson, Simon Heller, Ole Hels, Richard E. Pratley, Thozhukat Sathyapalan, Cyrus Desouza, R.N. Abramof, Diana N Alpenidze, S Aronoff, K. Astamirova, B Barker, Gary Bedel, Lidia Belousova, Mark D. Benson, Isaac Beshay, William Biggs, Kenneth Blaze, Paweł Bogdański, Robert S. Busch, Sushela Chaidarun, Siddharthan Chandran, Alex R. Chang, S Chilka, Alan S. Cleland, Lisa Connery, George Mitchell Cornett, Bruno Delgado, Cyrus Desouza, Thomas Donner, Ken Eliasson, Jan W. Eriksson, Steven Folkerth, Kristy Forshaw, Hans Frandsen, Elena Frolova, Winston Gandy, G Gatipon, Albina Golovach, L. Gonzalez-Orozco, Janusz Gumprecht, Élie Haddad, Troels Krarup Hansen, Thomas C. Hart, Syed Shahzad Hasan, Brent Hella, Simon Heller, Margareta Hellgren, Mark I. Hewitt, S Hietaniemi, Marc‐Phillip Hitz, P Houser, Raphael E. Huntley, R. A. JACKSON, Poul Erik Jakobsen, Anuj Pal Kapoor, L. Kargina, Elena Kazakova, Khalid Khan, E. Klein, H Knoble, N Krasnopeeva, Andre Krzeminski, М. А. Куницына, J Lawhead, Klaus Levin, Philip Levin, Lorena Lewy-Alterbaum, Stina Lindmark, Robert S. Lindsay, Alain Luts, Tatyana Lysenko, Sten Madsbad, Tyler Maxwell, Caroline Mbogua, JA McKnight, Kaj Metsärinne, Т. А. Милованова, Emily Morawski, Ofri Mosenzon, Dan Nabriski, Hai Quy Tram Nguyen, Philip Nicol, Sanna Nieminen, Anita Schwab Nikkola, Paul Norwood, Peter H. O’Donnell, A. Ola Odugbesan, Jeremy C. Parker, Y. Pergaeva, А. Б. Песков, S. Plevin, Joe Pouzar, Richard E. Pratley, Josh Reed, Peter Rossing, Thozhukat Sathyapalan, M. Sergeeva-Kondrachenko
The Lancet Diabetes & Endocrinology. 2019345 CitationsOPEN ACCESS
Related on ScholarIQ
Albany College of Pharmacy and Health Sciences
Institution
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Paper
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Paper
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Paper
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Paper
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Paper